Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis

M Malgorzata Gozdecka M Monika Dudek S Sean Wen M Muxin Gu R Richard J. Stopforth J Justyna Rak A Aristi Damaskou G Guinevere L. Grice M Matthew A. McLoughlin L Laura Bond R Rachael Wilson G George Giotopoulos V Vijaya Mahalingam Shanmugiah R Rula Bany Bakar E Eliza Yankova J Jonathan L. Cooper N Nisha Narayan S Sarah J. Horton R Ryan Asby D Dean C. Pask A Annalisa Mupo G Graham Duddy L Ludovica Marando T Theodoros Georgomanolis P Paul Carter A Amirtha Priya Ramesh W William G. Dunn C Clea Barcena P Paolo Gallipoli K Kosuke Yusa S Slavé Petrovski P Penny Wright P Pedro M. Quiros C Christian Frezza J James A. Nathan A Arthur Kaser S Siddhartha Kar K Konstantinos Tzelepis J Jonathan Mitchell M Margarete A. Fabre B Brian J. P. Huntly G George S. Vassiliou

Abstract

Abstract Somatic DNMT3A-R882 codon mutations drive the most common form of clonal haematopoiesis (CH) and are associated with increased acute myeloid leukaemia (AML) risk1,2. Preventing expansion of DNMT3A-R882-mutant haematopoietic stem/progenitor cells (HSPCs) may therefore avert progression to AML. To identify DNMT3A-R882-mutant-specific vulnerabilities, we conducted a genome-wide CRISPR screen on primary mouse Dnmt3a R882H/+ HSPCs. Among the 640 vulnerability genes identified, many were involved in mitochondrial metabolism, and metabolic flux analysis confirmed enhanced oxidative phosphorylation use in Dnmt3a R882H/+ versus Dnmt3a +/+ (WT) HSPCs. We selected citrate/malate transporter Slc25a1 and complex I component Ndufb11, for which pharmacological inhibitors are available, for downstream studies. In vivo administration of SLC25A1 inhibitor CTPI2 and complex I inhibitors IACS-010759 and metformin suppressed post-transplantation clonal expansion of Dnmt3a R882H/+, but not WT, long-term haematopoietic stem cells. The effect of metformin was recapitulated using a primary human DNMT3A-R882 CH sample. Notably, analysis of 412,234 UK Biobank participants showed that individuals taking metformin had a markedly lower prevalence of DNMT3A-R882-mutant CH, after controlling for potential confounders including glycated haemoglobin, diabetes and body mass index. Collectively, our data propose modulation of mitochondrial metabolism as a therapeutic strategy for prevention of DNMT3A-R882-mutant AML.

Article Details

Journal Nature
Volume / Issue Vol. 642, Issue 8067
Published June 12, 2025
Pages 431-441
ISSN 0028-0836
Publisher Nature Portfolio

Journal Info

Nature

Nature Portfolio

ISSN: 0028-0836 Health Sciences

Authors (42)

M

Malgorzata Gozdecka

M

Monika Dudek

S

Sean Wen

M

Muxin Gu

R

Richard J. Stopforth

J

Justyna Rak

A

Aristi Damaskou

G

Guinevere L. Grice

M

Matthew A. McLoughlin

L

Laura Bond

R

Rachael Wilson

G

George Giotopoulos

V

Vijaya Mahalingam Shanmugiah

R

Rula Bany Bakar

E

Eliza Yankova

J

Jonathan L. Cooper

N

Nisha Narayan

S

Sarah J. Horton

R

Ryan Asby

D

Dean C. Pask

A

Annalisa Mupo

G

Graham Duddy

L

Ludovica Marando

T

Theodoros Georgomanolis

P

Paul Carter

A

Amirtha Priya Ramesh

W

William G. Dunn

C

Clea Barcena

P

Paolo Gallipoli

K

Kosuke Yusa

S

Slavé Petrovski

P

Penny Wright

P

Pedro M. Quiros

C

Christian Frezza

J

James A. Nathan

A

Arthur Kaser

S

Siddhartha Kar

K

Konstantinos Tzelepis

J

Jonathan Mitchell

M

Margarete A. Fabre

B

Brian J. P. Huntly

G

George S. Vassiliou